Spero Therapeutics Inc. shares traded about 12% lower in pre-market activity on Tuesday after the company disclosed a $105 million licensing financing with affiliates of Healthcare Royalty, a unit of KKR.
Under the transaction, the KKR-related Healthcare Royalty affiliates - referred to as HCRx - acquired rights to a portion of future milestone and royalty streams linked to sales of Utebzi, the oral antibiotic also known as tebipenem pivoxil. Spero said the upfront proceeds will be allocated primarily to support development of SP001, its lead immunology candidate that is currently in Phase 2.
In a statement, Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics, said: "Over the past year, in collaboration with GSK, we successfully advanced Utebzi through FDA approval, while executing on our strategy to strengthen Spero and position the Company for its next phase of growth. This transaction further strengthens our balance sheet and provides non-dilutive capital as we embark on an immunology-focused strategy."
The financing closed contemporaneously with Spero's exclusive license agreement with Innovent Biologics for the SP001 asset. The company framed the arrangement as part of its shift toward an immunology-focused strategy following the recent regulatory milestone for Utebzi.
The company noted that Utebzi received U.S. approval last month for use in complicated urinary tract infections. Spero has granted GSK an exclusive license to develop and commercialize Utebzi in all territories except certain Asian markets where Meiji maintains rights.
Details of the financial mechanics were disclosed by Spero. HCRx will deliver $105 million at closing - net of the original issue discount and fees - in return for rights to payments from GSK associated with Utebzi sales. The HCRx arrangement calls for quarterly principal and interest distributions derived from the GSK payments until the loan balance is repaid. Once repayment is complete, Spero will retain 35% of subsequent GSK payments tied to Utebzi sales.
Following the close of the transaction, Spero adjusted its liquidity outlook and said the financing extends its cash runway guidance into the second half of 2029.
Context and implications
- Spero monetized a portion of future Utebzi revenue to secure near-term financing without issuing new equity.
- The capital is intended chiefly to fund SP001 development, reinforcing the companys stated pivot toward immunology programs.
- The deal structure links creditor payments directly to amounts received from GSK for Utebzi sales, with Spero reclaiming a material share of revenue after loan repayment.
What remains uncertain
- The pace and amount of future GSK payments tied to Utebzi sales are central to how quickly the financing will be repaid and when Spero will resume retaining a larger share of revenue.
- Market reaction included an immediate decline in Speros share price in pre-market trading, reflecting investor reassessment of the financing and its implications for future cash flows.
- The longer-term impact on Speros financial profile depends on execution of SP001s Phase 2 program and subsequent commercial dynamics for Utebzi, which are not detailed in the companys announcement.